Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study

Ramón García-Sanz, Roger G. Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen S. Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Open source

DOI: 10.1182/bloodadvances.2024015596
Published: 2025-12-15
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024015596,
  title = {Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study},
  author = {Ramón García-Sanz and Roger G. Owen and Wojciech Jurczak and Meletios A. Dimopoulos and Helen McCarthy and Gavin Cull and Stephen S. Opat and Jorge J. Castillo and Marie José Kersten and Björn E. Wahlin and Sebastian Grosicki and Radha Prathikanti and Tian Tian and Heather Allewelt and Aileen Cleary Cohen and Constantine S. Tam},
  year = {2025},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2024015596},
  url = {https://doi.org/10.1182/bloodadvances.2024015596}
}

RIS

TY  - JOUR
TI  - Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study
AU  - Ramón García-Sanz
AU  - Roger G. Owen
AU  - Wojciech Jurczak
AU  - Meletios A. Dimopoulos
AU  - Helen McCarthy
AU  - Gavin Cull
AU  - Stephen S. Opat
AU  - Jorge J. Castillo
AU  - Marie José Kersten
AU  - Björn E. Wahlin
AU  - Sebastian Grosicki
AU  - Radha Prathikanti
AU  - Tian Tian
AU  - Heather Allewelt
AU  - Aileen Cleary Cohen
AU  - Constantine S. Tam
PY  - 2025
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2024015596
UR  - https://doi.org/10.1182/bloodadvances.2024015596
ER  -

APA

García-Sanz, R., Owen, R. G., Jurczak, W., Dimopoulos, M. A., McCarthy, H., Cull, G., Opat, S. S., Castillo, J. J., Kersten, M. J., Wahlin, B. E., Grosicki, S., Prathikanti, R., Tian, T., Allewelt, H., Cohen, A. C., & Tam, C. S. (2025). Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015596

Source records

crossref · retrieved 2026-09-26T00:21:13.287Z